Revenue segments as reported by the company.

Clearing and transaction fees

Market data and information services

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Compensation and benefits  

Technology

Professional fees and outside services

Amortization of purchased intangibles

Depreciation and amortization

Licensing and other fee agreements

Other expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CME Group

CME Group, Inc. operates a derivatives marketplace, which offers a range of futures and options products for risk management. Its exchanges offer a range of global benchmark products across all major asset classes based on interest rates, equity indexes, foreign exchange (FX), energy, agricultural commodities and metals. It offers futures and options on futures trading across asset classes through the CME Globex platform, fixed income trading via BrokerTec and FX trading on the EBS platform. In addition, it also operates CME Clearing, a central counterparty clearing provider. The company was founded in 1898 and is headquartered in Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CME Group achieves record-breaking 2022 performance amidst market challenges

CME Group's 2022 performance was exceptional, marked by record volumes, revenue growth, and successful transitions. The company's focus on innovation, strategic positioning in energy and cryptocurrency markets, and pricing adjustments have driven positive outcomes. Challenges in margins and market uncertainties require careful navigation.

CME Group posts record Q1 earnings, eyes growth in SOFR

CME Group delivered a strong performance in Q1 2023, achieving record revenue and profitability driven by growth in interest rate and options trading.
The company's strategic focus on risk management, shareholder value creation, and market competitiveness positions it well for future growth and revenue generation.
While facing challenges in a competitive market environment, CME Group has opportunities to capitalize on the demand for SOFR products and options trading.
Optimism surrounding the company's future growth potential, coupled with effective expense management and revenue diversification, underpin its resilience and strategic outlook.

CME Group excels in Q2 with record revenue and strategic focus

CME Group's Q2 earnings call showcased strong financial performance, driven by growth across asset classes and a focus on customer-centric strategies. The company's emphasis on innovation, regulatory compliance, and market leadership positions it well for future growth.

CME Group reports strong Q3 earnings, eyes growth amid challenges

CME Group's Q3 2023 earnings call highlighted robust financial performance, operational efficiency, and strategic positioning. Despite facing regulatory challenges and cost management concerns, the company remains confident in its offerings and growth prospects. Opportunities for expansion through innovation and capitalizing on market trends were key discussion points.

CME Group achieves record 2023 results amidst global uncertainties

CME Group's record-breaking performance in 2023 underscores its market leadership and financial strength, with revenue growth, margin expansion, and strong product demand driving positive results.
While facing challenges from global uncertainties and market dynamics, the company's strategic focus on innovation, risk management, and efficiency positions it well to capitalize on opportunities in evolving markets.
By introducing new products, expanding partnerships, and navigating changing market conditions adeptly, CME Group demonstrates resilience and adaptability, paving the way for continued growth and success in the financial industry.
Overall, CME Group's strategic initiatives, financial performance, and market positioning reflect a company poised for sustained success, leveraging opportunities and strengths to overcome challenges and drive future growth.

CME Group achieves record earnings in Q1 2024, eyes growth

CME Group delivered a strong performance in Q1 2024, setting records in revenue and earnings.
The company faces challenges in managing expenses amid growth initiatives and competitive dynamics.
However, CME's strengths in market leadership, network infrastructure, and regulatory alignment position it well for future opportunities.
By capitalizing on data services and revenue growth avenues, CME can continue its upward trajectory in the market.

CME Group achieves record Q3 performance amidst regulatory challenges

CME Group's Q3 performance was exceptional, marked by record volumes and financial metrics. Despite challenges in regulatory compliance and competition, the company is well-positioned for growth through strategic opportunities in interest rate products and retail expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cboe Global Markets

A financial news outlet published a story that neither involved party is willing to confirm, and one of which is outright denying.

Why Shares of Cboe Global Markets Soared -- Then Gave It All Back -- on Wednesday

Volatility in CBOE shares was so extreme that trading was shuttered by the market's built-in circuit breakers.

CBOE whipsaws on reports of a possible CME acquisition, briefly halting trading in shares of the options exchange

Exchange operator CME Group Inc on Wednesday denied a media report that it approached rival Cboe Global Markets Inc with a $16 billion all-share takeover offer.

CME denies media report of $16 billion takeover bid for rival Cboe

Shares of Cboe Global Markets Inc. CBOE, -0.04% rose 1.5% in afternoon trading, but pulled back sharply, after CME Group Inc. CME, -2.52% denied that it had any discussions regarding a buyout of the rival exchange. Just prior to the denial, was up about 8.4%.

CME denies report of buyout bid for Cboe, saying 'inaccurate' report needed 'correction'

Share of Cboe Global Markets Inc. CBOE, +4.66% spiked up 7.4% in afternoon trading Wednesday, after the Financial Times reported that CME Group Inc. CME, -3.63% was making an all-stock bid valued at $16 billion to buy the revival exchange. "As a matter of policy, Cboe does not comment on market rumors or speculation," Cboe said in an emailed statement to MarketWatch.

Cboe stock spikes up after FT report of CME buyout bid

Nasdaq

OTC Markets Group Inc.

Product innovation, increased market volatility and a strategic economic market model are expected to aid Securities and Exchanges stocks like CBOE, CME, NDAQ and OTCM. However, compliance with regulations remains a challenge.

4 Securities and Exchanges to Watch Out For Amid Industry Challenges

CHICAGO, Aug. 9, 2021 /PRNewswire/ -- CME Group announced today that Julie Winkler, Chief Commercial Officer; Derek Sammann, Global Head of Commodities and Options Products; and Sean Tully, Global Head of Financial and OTC Products, will present at the UBS Financial Services Virtual Conference on Wednesday, August 11, 2021 at 8:00 a.m. (Eastern Time).

CME Group Chief Commercial Officer, Global Head of Commodities and Options Products, and Global Head of Financial and OTC Products to Present at UBS Financial Services Virtual Conference

Advanced Micro Devices

Siren Nasdaq NexGen Economy ETF

DocuSign

PayPal

Roundhill Ball Metaverse ETF

Blockchain stocks will benefit from the increased use of use blockchain-related products and services in areas other than crypto. The post 7 of the Best Blockchain Stocks to Buy in Lieu of Crypto appeared first on InvestorPlace.

7 of the Best Blockchain Stocks to Buy in Lieu of Crypto

Apple

Accenture Plc

Automatic Data Processing

Costco

Cisco Systems

General Dynamics

Home Depot

Honeywell

Intel

Johnson & Johnson

Eli Lilly

Lockheed Martin

Mastercard

Medtronic

Merck

Microsoft

NIKE

PepsiCo

Procter & Gamble

Stryker

Texas Instruments

Union Pacific

Visa

Walmart

This article updates one published by David Van Knapp in June 2020.

The Highest Quality Dividend Growth Stocks

CHICAGO, Aug. 3, 2021 /PRNewswire/ -- CME Group, the world's leading and most diverse derivatives marketplace, today reported July 2021 market statistics, including average daily volume (ADV) of 17.1 million contracts during the month. Market statistics are available in greater detail at https://cmegroupinc.gcs-web.com/monthly-volume.

CME Group Reports July 2021 Monthly Market Statistics

CME Group's (CME) Q2 results reflect higher market data and information services and lower expenses as well as increase in average daily volume in four of the six products lines.

CME Group (CME) Q2 Earnings Beat, Revenues Decrease Y/Y

CHICAGO, July 29, 2021 /PRNewswire/ -- CME Group, the world's leading and most diverse derivatives marketplace, today issued the following statement in response to the Alternative Reference Rates Committee's (ARRC) formal recommendation of CME Term SOFR Reference Rates for use based on their previously outlined best practices: "We are pleased to be selected by the ARRC to play this important role and have been delivering robust, forward-looking SOFR term rates to the industry, based on our deep and liquid underlying CME SOFR futures market, since September 2020," said Sean Tully, CME Group Global Head of Financial and OTC Products. "The ARRC's formal recommendation of CME Term SOFR Reference Rates is an important milestone for the industry and the continued development of the broader SOFR ecosystem.

CME Group Statement on ARRC Formal Recommendation of CME Term SOFR Reference Rates

CME's (CME) CEO Terry Duffy on Q2 2021 Results - Earnings Call Transcript

CME (CME) delivered earnings and revenue surprises of 3.14% and 0.81%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

CME Group (CME) Q2 Earnings and Revenues Beat Estimates

Shares of CME Group (NASDAQ:CME) rose 1.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 0.61% over the past year to $1.64, which beat the estimate of $1.61.

Recap: CME Group Q2 Earnings

CME Group Inc reported a 1.4% rise in second-quarter profit on Wednesday, helped by lower expenses and higher trading across asset classes.

Exchange operator CME Group's profit rises in second quarter

CHICAGO, July 28, 2021 /PRNewswire/ -- CME Group Inc. (NASDAQ: CME) today reported financial results for the second quarter of 2021. The company reported revenue of $1.2 billion and operating income of $675 million for the second quarter of 2021.

CME Group Inc. Reports Second-Quarter 2021 Financial Results

CME Group (NASDAQ: CME) is scheduled to report its fiscal Q2 2021 results on Wednesday, July 28. We expect CME Group﻿CME﻿ to top the consensus estimates for revenues and earnings.

What To Expect From CME Group Stock In Q2?

CME Group's (CME) Q2 results are likely to reflect lower clearing and transaction fees and other revenues, and higher expenses. However, market data and information services revenues are expected to have been higher.

CME Group (CME) to Report Q2 Earnings: What's in the Cards?

CME (CME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: CME Group (CME) Q2 Earnings Expected to Decline

LONDON and SINGAPORE, July 12, 2021 /PRNewswire/ -- CME Group, the world's leading and most diverse derivatives marketplace, today announced that its international average daily volume (ADV) reached 5.1 million contracts in Q2 2021, up 6% year on year. Reflecting all trading done outside North America, this volume was driven by global growth in Agricultural and Interest Rate products, up 30% and 42% respectively.

CME Group International Average Daily Volume Reached 5.1 Million Contracts in Q2 2021, Up 6% from Q2 2020

CME Group's (CME) Q2 average daily volumes reflect higher volumes in four of the six product lines.

CME Group (CME) Q2 Volumes Increase Y/Y in Four Product Lines

CHICAGO, July 2, 2021 /PRNewswire/ -- CME Group, the world's leading and most diverse derivatives marketplace, today reported its Q2 and June 2021 market statistics, showing it reached average daily volume (ADV) of 18.4 million contracts for both the second quarter and the month of June. Market statistics are available in greater detail at https://cmegroupinc.gcs-web.com/monthly-volume.

CME Group Reports Q2 and June 2021 Monthly Market Statistics

CME Group (CME) is poised to grow, given its market data distribution channels, higher custody fees and prudent capital deployment.

Why Should You Retain CME Group (CME) in Your Portfolio?

LONDON and CHICAGO, June 24, 2021 /PRNewswire/ -- CME Group, the world's leading and most diverse derivatives marketplace, today announced that market data and order entry functionality for FX Link are now available on the Bloomberg Terminal to enable market participants to electronically access pricing, liquidity and trading for FX swaps in G5 currency pairs. The integration provides mutual clients with access to new FX futures contracts through Bloomberg's ISV, Tradebook.

News for CME Group Stock (CME)